Imbed Biosciences
Madison, US · Founded 2010 · Wisconsin corporation · 1 known investors
Imbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.
Founders & leadership
Imbed Biosciences was founded in 2010 by Nicholas L Abbott and Ankit Agarwal.
NL
Nicholas L AbbottCo-founder
AA
Ankit AgarwalCo-founder
Board
DG
David GuintherBoard director
RA
Robert A BeckmanBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$22.3M disclosed across 8 rounds · 2014–2023
▶$3.5MraisedDec 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedDec 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip FosterDirector
- Ankit AgarwalExecutive Officer, Director
- Walter DeweyDirector
- David GuintherDirector
- Jonathan BlackDirector
- Elizabeth TaylorExecutive Officer
- Offering amount
- $3.6M
- Amount sold
- $3.5M
- First sale
- Dec 2023
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$2.5MraisedMay 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMay 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David GuintherDirector
- Jonathan BlackExecutive Officer, Director
- Ankit AgarwalExecutive Officer, Director
- Elizabeth TaylorExecutive Officer
- Walter DeweyDirector
- Philip FosterDirector
- Offering amount
- $6M
- Amount sold
- $2.5M
- Minimum investment
- $35K
- First sale
- May 2023
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$7.9MraisedNov 2021 · 37 investors · BiotechnologyRule 506(b)
▶$7.9MraisedNov 2021 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David GuintherDirector
- Jeff HansonDirector
- Michael J. SchurrDirector
- Elizabeth B. TaylorDirector
- Ankit AgarwalExecutive Officer, Director
- Offering amount
- $14.2M
- Amount sold
- $7.9M
- First sale
- Nov 2021
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$1.5MraisedJun 2020 · 18 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJun 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. SchurrDirector
- Ankit AgarwalExecutive Officer, Director
- David GuintherDirector
- Jeff HansonDirector
- Elizabeth B. TaylorDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$4MraisedOct 2019 · 47 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2019 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael SchurrDirector
- Elizabeth B. TaylorDirector
- David GuintherDirector
- Nicholas L AbbottExecutive Officer, Director
- Ankit AgarwalExecutive Officer, Director
- Robert A. BeckmanDirector
- Offering amount
- $4.1M
- Amount sold
- $4M
- First sale
- Oct 2018
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$1.6MraisedDec 2017 · 11 investors · BiotechnologyRule 506(b)
▶$1.6MraisedDec 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ankit AgarwalExecutive Officer, Director
- Robert A. BeckmanDirector
- Nicholas L AbbottExecutive Officer, Director
- David GuintherDirector
- Offering amount
- $1.7M
- Amount sold
- $1.6M
- First sale
- Dec 2017
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$600KraisedAug 2016 · 3 investors · BiotechnologyRule 506(b)
▶$600KraisedAug 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas L AbbottExecutive Officer, Director
- David GuintherDirector
- Robert A BeckmanDirector
- Ankit AgarwalExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $600K
- Minimum investment
- $25K
- First sale
- Aug 2016
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$683.3KraisedSep 2014 · 8 investors · BiotechnologyRule 506(b)
▶$683.3KraisedSep 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas L AbbottExecutive Officer, Director
- Ankit AgarwalExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $683.3K
- Minimum investment
- $25K
- First sale
- Apr 2014
- Incorporated
- Corporation, Wisconsin, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Imbed Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $806.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Science Foundation | Phase I | 2014 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $326.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Imbed Biosciences do?
- Imbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.
- Who founded Imbed Biosciences?
- Imbed Biosciences was founded by Nicholas L Abbott, Ankit Agarwal in 2010.
- Who are Imbed Biosciences's investors?
- Imbed Biosciences's investors include Wisconsin Investment Partners.
- How much funding has Imbed Biosciences raised?
- Imbed Biosciences has disclosed $22.3M raised across 8 rounds.
- Where is Imbed Biosciences headquartered?
- Imbed Biosciences is headquartered in Madison, US.